Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like MV Agusta launches Brutale 800 at Rs15.59 lakh, eyes 20% of superbike pie by 2020 July 19, 2017 How Additive Manufacturing Drives Sustainable Manufacturing August 21, 2019 General Motors to cut 1,100 Michigan jobs as SUV output shifts to Tennessee March 7, 2017